secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-003717
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint
----------------------------------------------------------------------------

- Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.
- Lung Diagnostic revenue $64.7M (+43% YoY); test volumes 54,300 (+40% YoY).
- Biopharma Services revenue $6.6M (+69% YoY); $12.2M contracted backlog for 2025 (+54%).
- Cash and equivalents $26.2M as of Dec 31, 2024.
- Results are preliminary and unaudited; Q4 and FY2024 figures subject to final audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017025003717/0000950170-25-003717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017025003717/bdsx-20250110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer